NCBI Home Page NCBI Site Search page NCBI Guide that lists and describes the NCBI resources
Conserved domains on  [gi|1778700917|ref|WP_154870712|]
View 

MULTISPECIES: aminopeptidase N [Serratia]

Protein Classification

M1 family metallopeptidase( domain architecture ID 11487037)

M1 family metallopeptidase is a zinc-dependent metallopeptidase that functions as an aminopeptidase and contains an HEXXH motif as part of its active site; such as aminopeptidase N, which is a type II integral membrane protease that preferentially cleaves neutral amino acids from the N-terminus of oligopeptides

Graphical summary

 Zoom to residue level

show extra options »

Show site features     Horizontal zoom: ×

List of domain hits

Name Accession Description Interval E-value
pepN PRK14015
aminopeptidase N; Provisional
1-872 0e+00

aminopeptidase N; Provisional


:

Pssm-ID: 237585 [Multi-domain]  Cd Length: 875  Bit Score: 1706.10  E-value: 0e+00
                          10        20        30        40        50        60        70        80
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 1778700917   1 MTQQPQAKYRHDYRAPDYTTTDIDLDFSLDAETTRVTAVSKIKRQGAAG--APLVLDGEDLTLVSIQVDGQPWS--AYRQ 76
Cdd:PRK14015    2 RTQQPQAIYLKDYRPPDYLIDTVDLDFDLDPDKTRVTARLQVRRNPDAAhsAPLVLDGEDLELLSLALDGQPLApsAYEL 81
                          90       100       110       120       130       140       150       160
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 1778700917  77 QDNQLIIEELPAQFTLTIVNDIHPAKNTALEGLYLSGDALCTQCEAEGFHHITYYQDRPDVLARFTTRIVADKTRYPFLL 156
Cdd:PRK14015   82 DEEGLTIENLPDRFTLEIETEIDPEANTALEGLYRSGGMFCTQCEAEGFRRITYFLDRPDVLARYTVRIEADKAKYPVLL 161
                         170       180       190       200       210       220       230       240
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 1778700917 157 SNGNRIGQGELADGRHWVQWQDPFPKPCYLFALVAGDFDVLRDSFTTRSGRKVALELFVDRGNLDRADWAMTSLKNSMKW 236
Cdd:PRK14015  162 SNGNLVESGELPDGRHWATWEDPFPKPSYLFALVAGDLDVLEDTFTTRSGREVALEIYVEPGNLDKCDHAMDSLKKSMKW 241
                         250       260       270       280       290       300       310       320
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 1778700917 237 DETRFGLEYDLDIYMIVAVDFFNMGAMENKGLNIFNSKYVLAKAETATDKDYLNIEAVIGHEYFHNWTGNRVTCRDWFQL 316
Cdd:PRK14015  242 DEERFGLEYDLDIFMIVAVDDFNMGAMENKGLNIFNSKYVLADPETATDADYERIESVIAHEYFHNWTGNRVTCRDWFQL 321
                         330       340       350       360       370       380       390       400
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 1778700917 317 SLKEGLTVFRDQEFSSDLGSRSVNRIDNVRVMRGAQFAEDASPMAHAIRPDKVIEMNNFYTLTVYEKGSEVIRMMHTLLG 396
Cdd:PRK14015  322 SLKEGLTVFRDQEFSADLGSRAVKRIEDVRVLRAAQFAEDAGPMAHPVRPDSYIEINNFYTATVYEKGAEVIRMLHTLLG 401
                         410       420       430       440       450       460       470       480
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 1778700917 397 EENFQKGMQLYFERHDGSAATCDDFVQAMEDASNVDLSRFRRWYSQSGTPLLTVRDEYDAETQQYRLHVSQKTAPTADQP 476
Cdd:PRK14015  402 EEGFRKGMDLYFERHDGQAVTCEDFVAAMEDASGRDLSQFRRWYSQAGTPRVTVSDEYDAAAGTYTLTLSQSTPPTPGQP 481
                         490       500       510       520       530       540       550       560
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 1778700917 477 EKLPLHIPLDIELYDSEGNVIPLQKGGLPVNNVLNVTEAEQTFVFDGVAHKPVPSLLREFSAPVKLDYPYSDQQLTFLMQ 556
Cdd:PRK14015  482 EKQPLHIPVAIGLLDPDGKELPLQLEGEPVERVLELTEAEQTFTFENVAERPVPSLLRGFSAPVKLEYDYSDEDLLFLMA 561
                         570       580       590       600       610       620       630       640
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 1778700917 557 HARNEFARWDAAQSLLATYIKLNVARHqqKQPLSLPLHVADAFRAVLLDEKLDPALAAQILTLPSENEIAELFATIDPEA 636
Cdd:PRK14015  562 HDSDPFNRWEAGQRLATRLLLANVARH--GQPLSLDEALIDAFRAVLLDESLDPAFAAELLTLPSEAELAEQMEVIDPDA 639
                         650       660       670       680       690       700       710       720
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 1778700917 637 IAAVHEAIVRCLARELADEWLAVYHANKTDG-YRVEHAEIAKRALRNVCLGYLAFGEDvALADQLVNEQYRQADNMTDAL 715
Cdd:PRK14015  640 IHAAREALRRALATALKDELLALYEALQTDGpYSPDAEAAGRRALRNVCLSYLAAADD-EEAAELAEAQFDQADNMTDRL 718
                         730       740       750       760       770       780       790       800
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 1778700917 716 AALSAAVAAQLPCRDALLAAFDERWHQDGLVMDKWFVLQGGSPAADVLSKVRALLHHRSFSLSNPNRTRSLIGGFASGNP 795
Cdd:PRK14015  719 AALSALVNADLPERDEALADFYDRWKDDPLVMDKWFALQATSPAPDTLERVRALMQHPAFDLKNPNRVRSLIGAFAAANP 798
                         810       820       830       840       850       860       870
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*..
gi 1778700917 796 AAFHAADGSGYQFLAEILSDLNQRNPQIAARLIEPLIRLKRYDAGRQALMRKALEQLKGLENLSGDLYEKISKALDA 872
Cdd:PRK14015  799 AGFHAADGSGYRFLADQILALDKINPQVAARLATPLIRWRRYDPKRQALMRAALERIAALPNLSKDVREIVSKALAA 875
 
Name Accession Description Interval E-value
pepN PRK14015
aminopeptidase N; Provisional
1-872 0e+00

aminopeptidase N; Provisional


Pssm-ID: 237585 [Multi-domain]  Cd Length: 875  Bit Score: 1706.10  E-value: 0e+00
                          10        20        30        40        50        60        70        80
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 1778700917   1 MTQQPQAKYRHDYRAPDYTTTDIDLDFSLDAETTRVTAVSKIKRQGAAG--APLVLDGEDLTLVSIQVDGQPWS--AYRQ 76
Cdd:PRK14015    2 RTQQPQAIYLKDYRPPDYLIDTVDLDFDLDPDKTRVTARLQVRRNPDAAhsAPLVLDGEDLELLSLALDGQPLApsAYEL 81
                          90       100       110       120       130       140       150       160
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 1778700917  77 QDNQLIIEELPAQFTLTIVNDIHPAKNTALEGLYLSGDALCTQCEAEGFHHITYYQDRPDVLARFTTRIVADKTRYPFLL 156
Cdd:PRK14015   82 DEEGLTIENLPDRFTLEIETEIDPEANTALEGLYRSGGMFCTQCEAEGFRRITYFLDRPDVLARYTVRIEADKAKYPVLL 161
                         170       180       190       200       210       220       230       240
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 1778700917 157 SNGNRIGQGELADGRHWVQWQDPFPKPCYLFALVAGDFDVLRDSFTTRSGRKVALELFVDRGNLDRADWAMTSLKNSMKW 236
Cdd:PRK14015  162 SNGNLVESGELPDGRHWATWEDPFPKPSYLFALVAGDLDVLEDTFTTRSGREVALEIYVEPGNLDKCDHAMDSLKKSMKW 241
                         250       260       270       280       290       300       310       320
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 1778700917 237 DETRFGLEYDLDIYMIVAVDFFNMGAMENKGLNIFNSKYVLAKAETATDKDYLNIEAVIGHEYFHNWTGNRVTCRDWFQL 316
Cdd:PRK14015  242 DEERFGLEYDLDIFMIVAVDDFNMGAMENKGLNIFNSKYVLADPETATDADYERIESVIAHEYFHNWTGNRVTCRDWFQL 321
                         330       340       350       360       370       380       390       400
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 1778700917 317 SLKEGLTVFRDQEFSSDLGSRSVNRIDNVRVMRGAQFAEDASPMAHAIRPDKVIEMNNFYTLTVYEKGSEVIRMMHTLLG 396
Cdd:PRK14015  322 SLKEGLTVFRDQEFSADLGSRAVKRIEDVRVLRAAQFAEDAGPMAHPVRPDSYIEINNFYTATVYEKGAEVIRMLHTLLG 401
                         410       420       430       440       450       460       470       480
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 1778700917 397 EENFQKGMQLYFERHDGSAATCDDFVQAMEDASNVDLSRFRRWYSQSGTPLLTVRDEYDAETQQYRLHVSQKTAPTADQP 476
Cdd:PRK14015  402 EEGFRKGMDLYFERHDGQAVTCEDFVAAMEDASGRDLSQFRRWYSQAGTPRVTVSDEYDAAAGTYTLTLSQSTPPTPGQP 481
                         490       500       510       520       530       540       550       560
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 1778700917 477 EKLPLHIPLDIELYDSEGNVIPLQKGGLPVNNVLNVTEAEQTFVFDGVAHKPVPSLLREFSAPVKLDYPYSDQQLTFLMQ 556
Cdd:PRK14015  482 EKQPLHIPVAIGLLDPDGKELPLQLEGEPVERVLELTEAEQTFTFENVAERPVPSLLRGFSAPVKLEYDYSDEDLLFLMA 561
                         570       580       590       600       610       620       630       640
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 1778700917 557 HARNEFARWDAAQSLLATYIKLNVARHqqKQPLSLPLHVADAFRAVLLDEKLDPALAAQILTLPSENEIAELFATIDPEA 636
Cdd:PRK14015  562 HDSDPFNRWEAGQRLATRLLLANVARH--GQPLSLDEALIDAFRAVLLDESLDPAFAAELLTLPSEAELAEQMEVIDPDA 639
                         650       660       670       680       690       700       710       720
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 1778700917 637 IAAVHEAIVRCLARELADEWLAVYHANKTDG-YRVEHAEIAKRALRNVCLGYLAFGEDvALADQLVNEQYRQADNMTDAL 715
Cdd:PRK14015  640 IHAAREALRRALATALKDELLALYEALQTDGpYSPDAEAAGRRALRNVCLSYLAAADD-EEAAELAEAQFDQADNMTDRL 718
                         730       740       750       760       770       780       790       800
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 1778700917 716 AALSAAVAAQLPCRDALLAAFDERWHQDGLVMDKWFVLQGGSPAADVLSKVRALLHHRSFSLSNPNRTRSLIGGFASGNP 795
Cdd:PRK14015  719 AALSALVNADLPERDEALADFYDRWKDDPLVMDKWFALQATSPAPDTLERVRALMQHPAFDLKNPNRVRSLIGAFAAANP 798
                         810       820       830       840       850       860       870
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*..
gi 1778700917 796 AAFHAADGSGYQFLAEILSDLNQRNPQIAARLIEPLIRLKRYDAGRQALMRKALEQLKGLENLSGDLYEKISKALDA 872
Cdd:PRK14015  799 AGFHAADGSGYRFLADQILALDKINPQVAARLATPLIRWRRYDPKRQALMRAALERIAALPNLSKDVREIVSKALAA 875
pepN_proteo TIGR02414
aminopeptidase N, Escherichia coli type; The M1 family of zinc metallopeptidases contains a ...
12-870 0e+00

aminopeptidase N, Escherichia coli type; The M1 family of zinc metallopeptidases contains a number of distinct, well-separated clades of proteins with aminopeptidase activity. Several are designated aminopeptidase N, EC 3.4.11.2, after the Escherichia coli enzyme, suggesting a similar activity profile (see SP|P04825 for a description of catalytic activity). This family consists of all aminopeptidases closely related to E. coli PepN and presumed to have similar (not identical) function. Nearly all are found in Proteobacteria, but members are found also in Cyanobacteria, plants, and apicomplexan parasites. This family differs greatly in sequence from the family of aminopeptidases typified by Streptomyces lividans PepN (TIGR02412), from the membrane bound aminopeptidase N family in animals, etc. [Protein fate, Degradation of proteins, peptides, and glycopeptides]


Pssm-ID: 274122 [Multi-domain]  Cd Length: 863  Bit Score: 1350.83  E-value: 0e+00
                          10        20        30        40        50        60        70        80
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 1778700917  12 DYRAPDYTTTDIDLDFSLDAETTRVTAVSKIKRQG-AAGAPLVLDGEDLTLVSIQVDGQPWSA--YRQQDNQLIIEELPA 88
Cdd:TIGR02414   1 DYKPPPFLIEKTHLDFDLHEEETVVRARLTVRRNPdGNGAPLVLDGEELKLLSIAIDGKPLAAgdYQLDDETLTIASVPE 80
                          90       100       110       120       130       140       150       160
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 1778700917  89 QFTLTIVNDIHPAKNTALEGLYLSGDALCTQCEAEGFHHITYYQDRPDVLARFTTRIVADKTRYPFLLSNGNRIGQGELA 168
Cdd:TIGR02414  81 SFTLEIETEIHPEENTSLEGLYKSGGNFCTQCEAEGFRRITYFPDRPDVMSRYTVTITADKKKYPVLLSNGNKIASGELP 160
                         170       180       190       200       210       220       230       240
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 1778700917 169 DGRHWVQWQDPFPKPCYLFALVAGDFDVLRDSFTTRSGRKVALELFVDRGNLDRADWAMTSLKNSMKWDETRFGLEYDLD 248
Cdd:TIGR02414 161 DGRHWAEWEDPFPKPSYLFALVAGDLDVLEDTFTTKSGREVALRVYVEEGNKDKCDHAMESLKKAMKWDEEVFGLEYDLD 240
                         250       260       270       280       290       300       310       320
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 1778700917 249 IYMIVAVDFFNMGAMENKGLNIFNSKYVLAKAETATDKDYLNIEAVIGHEYFHNWTGNRVTCRDWFQLSLKEGLTVFRDQ 328
Cdd:TIGR02414 241 IFMIVAVDDFNMGAMENKGLNIFNSKYVLADPETATDADYERIESVIAHEYFHNWTGNRVTCRDWFQLSLKEGLTVFRDQ 320
                         330       340       350       360       370       380       390       400
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 1778700917 329 EFSSDLGSRSVNRIDNVRVMRGAQFAEDASPMAHAIRPDKVIEMNNFYTLTVYEKGSEVIRMMHTLLGEENFQKGMQLYF 408
Cdd:TIGR02414 321 EFSADMTSRAVKRIEDVRLLRAHQFPEDAGPMAHPVRPESYVEINNFYTATVYEKGAEVIRMLHTLLGEEGFRKGMDLYF 400
                         410       420       430       440       450       460       470       480
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 1778700917 409 ERHDGSAATCDDFVQAMEDASNVDLSRFRRWYSQSGTPLLTVRDEYDAETQQYRLHVSQKTAPTADQPEKLPLHIPLDIE 488
Cdd:TIGR02414 401 SRHDGQAVTCEDFVAAMEDASGRDLNQFRRWYSQAGTPVLEVKENYDAAKKTYTLTVRQSTPPTPGQTEKKPLHIPIAVG 480
                         490       500       510       520       530       540       550       560
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 1778700917 489 LYDSEGNVIPLQ-KGGLPVNNVLNVTEAEQTFVFDGVAHKPVPSLLREFSAPVKLDYPYSDQQLTFLMQHARNEFARWDA 567
Cdd:TIGR02414 481 LLGPNGRKLMLSlDGERDTTRVLELTEAEQTFVFEGIAEKPVPSLLRGFSAPVNLEYPYSDEDLLLLLAHDSDPFNRWEA 560
                         570       580       590       600       610       620       630       640
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 1778700917 568 AQSLLATYIKLNVARHQQKQPLSLPLHVADAFRAVLLDEKLDPALAAQILTLPSENEIAELFATIDPEAIAAVHEAIVRC 647
Cdd:TIGR02414 561 GQRLARRVILANIARAQGGEELPVDPAFIDALGKLLNDPHLDAAFKALLLALPSEAYLAELMENIDPDALHAAREFLRAA 640
                         650       660       670       680       690       700       710       720
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 1778700917 648 LARELADEWLAVYHANKTDG-YRVEHAEIAKRALRNVCLGYLAFGEDvALADQLVNEQYRQADNMTDALAALSAAVAAQL 726
Cdd:TIGR02414 641 IARQLADDLLRLYDALQENGpYSVDPAAAGRRALRNACLSYLSAADD-AEIRNLALEQFKSADNMTDRLAALSALVHFES 719
                         730       740       750       760       770       780       790       800
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 1778700917 727 PCRDALLAAFDERWHQDGLVMDKWFVLQGGSPAADVLSKVRALLHHRSFSLSNPNRTRSLIGGFASGNPAAFHAADGSGY 806
Cdd:TIGR02414 720 DFRERALAAFYQKWKDDPLVMDKWFALQATSPRPDTLERVKALLQHPAFDLKNPNRVRALIGAFANNNLVRFHDISGSGY 799
                         810       820       830       840       850       860
                  ....*....|....*....|....*....|....*....|....*....|....*....|....
gi 1778700917 807 QFLAEILSDLNQRNPQIAARLIEPLIRLKRYDAGRQALMRKALEQLKGLENLSGDLYEKISKAL 870
Cdd:TIGR02414 800 RFLADQIIAIDRFNPQVAARLLEPLTRWRKLDPKRQELMKAALERIAAEENLSKDVREVVSKAL 863
M1_APN cd09600
Peptidase M1 family, including aminopeptidase N catalytic domain; This model represents the ...
12-441 0e+00

Peptidase M1 family, including aminopeptidase N catalytic domain; This model represents the catalytic domain of aminopeptidase N (APN; CD13; alanyl aminopeptidase; EC 3.4.11.2), a type II integral membrane protease belonging to the M1 gluzincin family. It includes bacterial-type alanyl aminopeptidases as well as PfA-M1 aminopeptidase (Plasmodium falciparum-type). APN preferentially cleaves neutral amino acids from the N-terminus of oligopeptides and, in higher eukaryotes, is present in a variety of human tissues and cell types (leukocyte, fibroblast, endothelial and epithelial cells). APN expression is dysregulated in inflammatory diseases such as chronic pain, rheumatoid arthritis, multiple sclerosis, systemic sclerosis, systemic lupus erythematosus, polymyositis/dermatomyosytis and pulmonary sarcoidosis, and is enhanced in tumor cells such as melanoma, renal, prostate, pancreas, colon, gastric and thyroid cancers. It is predominantly expressed on stem cells and on cells of the granulocytic and monocytic lineages at distinct stages of differentiation, thus considered a marker of differentiation. Thus, APN inhibition may lead to the development of anti-cancer and anti-inflammatory drugs. APNs are also present in many pathogenic bacteria and represent potential drug targets. Some APNs have been used commercially, such as one from Lactococcus lactis used in the food industry. APN also serves as a receptor for coronaviruses, although the virus receptor interaction site seems to be distinct from the enzymatic site and aminopeptidase activity is not necessary for viral infection. APNs have also been extensively studied as putative Cry toxin receptors. Cry1 proteins are pore-forming toxins that bind to the midgut epithelial cell membrane of susceptible insect larvae, causing extensive damage. Several different toxins, including Cry1Aa, Cry1Ab, Cry1Ac, Cry1Ba, Cry1Ca and Cry1Fa, have been shown to bind to APNs; however, a direct role of APN in cytotoxicity has been yet to be firmly established.


Pssm-ID: 341063 [Multi-domain]  Cd Length: 434  Bit Score: 868.76  E-value: 0e+00
                          10        20        30        40        50        60        70        80
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 1778700917  12 DYRAPDYTTTDIDLDFSLDAETTRVTAVSKIKRQGAA--GAPLVLDGEDLTLVSIQVDGQP--WSAYRQQDNQLIIEELP 87
Cdd:cd09600     1 DYKPPDFLIDHVDLDFDLDDDETIVTSRLRVRRNPDSgeGAPLVLDGEDLELLSVKIDGKPlsPSDYTLDEEGLTIKNVP 80
                          90       100       110       120       130       140       150       160
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 1778700917  88 AQFTLTIVNDIHPAKNTALEGLYLSGDALCTQCEAEGFHHITYYQDRPDVLARFTTRIVADKTRYPFLLSNGNRIGQGEL 167
Cdd:cd09600    81 DRFVLEIEVRINPAANTSLEGLYKSGGILCTQCEAEGFRRITYFPDRPDVMSKFTVTIEADKEKYPVLLSNGNLIEEGEL 160
                         170       180       190       200       210       220       230       240
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 1778700917 168 ADGRHWVQWQDPFPKPCYLFALVAGDFDVLRDSFTTRSGRKVALELFVDRGNLDRADWAMTSLKNSMKWDETRFGLEYDL 247
Cdd:cd09600   161 PNGRHFAVWEDPFPKPSYLFALVAGDLGSVEDTFTTKSGRKVKLRIYVEPGNEDKCHHAMESLKKAMKWDEERFGLEYDL 240
                         250       260       270       280       290       300       310       320
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 1778700917 248 DIYMIVAVDFFNMGAMENKGLNIFNSKYVLAKAETATDKDYLNIEAVIGHEYFHNWTGNRVTCRDWFQLSLKEGLTVFRD 327
Cdd:cd09600   241 DLFNIVAVDDFNMGAMENKGLNIFNSKYVLADPETATDADYERIESVIAHEYFHNWTGNRVTCRDWFQLSLKEGLTVFRD 320
                         330       340       350       360       370       380       390       400
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 1778700917 328 QEFSSDLGSRSVNRIDNVRVMRGAQFAEDASPMAHAIRPDKVIEMNNFYTLTVYEKGSEVIRMMHTLLGEENFQKGMQLY 407
Cdd:cd09600   321 QEFSADMNSRAVKRIEDVRRLRSAQFPEDAGPMAHPIRPDSYIEINNFYTVTVYEKGAEVIRMLHTLLGEEGFRKGMDLY 400
                         410       420       430
                  ....*....|....*....|....*....|....
gi 1778700917 408 FERHDGSAATCDDFVQAMEDASNVDLSRFRRWYS 441
Cdd:cd09600   401 FERHDGQAVTCEDFVAAMEDASGRDLSQFKRWYS 434
PepN COG0308
Aminopeptidase N, contains DUF3458 domain [Amino acid transport and metabolism];
10-649 0e+00

Aminopeptidase N, contains DUF3458 domain [Amino acid transport and metabolism];


Pssm-ID: 440077 [Multi-domain]  Cd Length: 609  Bit Score: 576.59  E-value: 0e+00
                          10        20        30        40        50        60        70        80
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 1778700917  10 RHDYRAPDYTTTDIDLDFSLDAETTRVTAVSKI--KRQGAAGAPLVLDGEDLTLVSIQVDGQPWsAYRQQDNQLII---E 84
Cdd:COG0308     7 LEAYRPPGYDVTHYDLDLDLDPATTRLSGTATItfTATEAPLDSLVLDLKGLEVTSVTVDGKPL-DFTRDGERLTItlpK 85
                          90       100       110       120       130       140       150       160
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 1778700917  85 ELPA--QFTLTIVNDIHPakNTALEGLYLSGDA------LCTQCEAEGFHhiTYY--QDRPDVLARFTTRIVADKtrYPF 154
Cdd:COG0308    86 PLAPgeTFTLEIEYSGKP--SNGGEGLYRSGDPpdgppyLYTQCEPEGAR--RWFpcFDHPDDKATFTLTVTVPA--GWV 159
                         170       180       190       200       210       220       230       240
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 1778700917 155 LLSNGNRIGQGELADGRHWVQWQDPFPKPCYLFALVAGDFDVLRDSFttRSGrkVALELFVDRGNLDRADWAMTSLKNSM 234
Cdd:COG0308   160 AVSNGNLVSETELGDGRTTWHWADTQPIPTYLFALAAGDYAVVEDTF--ASG--VPLRVYVRPGLADKAKEAFESTKRML 235
                         250       260       270       280       290       300       310       320
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 1778700917 235 KWDETRFGLEYDLDIYMIVAVDFFNMGAMENKGLNIFNSKYVLAkaETATDKDYLNIEAVIGHEYFHNWTGNRVTCRDWF 314
Cdd:COG0308   236 DFFEELFGVPYPFDKYDQVAVPDFNFGAMENQGLVTFGEKVLAD--ETATDADYERRESVIAHELAHQWFGNLVTCADWD 313
                         330       340       350       360       370       380       390       400
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 1778700917 315 QLSLKEGLTVFRDQEFSSDLGSRS-VNRIDnVRVMRGAQFAEDASPMAHAIRPDKVIEMNNFYTLTVYEKGSEVIRMMHT 393
Cdd:COG0308   314 DLWLNEGFATYMEQLFSEDLYGKDaADRIF-VGALRSYAFAEDAGPNAHPIRPDDYPEIENFFDGIVYEKGALVLHMLRT 392
                         410       420       430       440       450       460       470       480
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 1778700917 394 LLGEENFQKGMQLYFERHDGSAATCDDFVQAMEDASNVDLSR-FRRWYSQSGTPLLTVRDEYDAETqQYRLHVSQKtapt 472
Cdd:COG0308   393 LLGDEAFRAGLRLYFARHAGGNATTEDFLAALEEASGRDLSAfFDQWLYQAGLPTLEVEYEYDADG-KVTLTLRQT---- 467
                         490       500       510       520       530       540       550       560
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 1778700917 473 adQPEKLPLHIPLDIELYDsegnviplqkGGLPVNNVLnVTEAEQTFVfdgvaHKPVpsllrefsaPVKLDYPysDQQLT 552
Cdd:COG0308   468 --PPRPHPFHIPLEVGLLG----------GKLTARTVL-LDGEQTELV-----AKPD---------PVLLLRL--DDELA 518
                         570       580       590       600       610       620       630       640
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 1778700917 553 FLMQHARNEFARWDAAQSLlatyiklnvARHQQKQPLSLPLHVADAfravlldeklDPALAAQILTLPSENEIAELFATI 632
Cdd:COG0308   519 FLLAHDSDPFNRWEALQAL---------WRDGEADYLDALRALADT----------DPAVRAEALALLGSDQLALARAAL 579
                         650
                  ....*....|....*..
gi 1778700917 633 DPEAIAAVHEAIVRCLA 649
Cdd:COG0308   580 ALAAELALLRALDDLLA 596
DUF3458_C pfam17432
Domain of unknown function (DUF3458_C) ARM repeats; This presumed domain is functionally ...
548-871 8.43e-159

Domain of unknown function (DUF3458_C) ARM repeats; This presumed domain is functionally uncharacterized. This domain is found in bacteria, archaea and eukaryotes.


Pssm-ID: 465424 [Multi-domain]  Cd Length: 324  Bit Score: 466.61  E-value: 8.43e-159
                          10        20        30        40        50        60        70        80
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 1778700917 548 DQQLTFLMQHARNEFARWDAAQSLLATYIKLNVARHQQKQPLSLPLHVADAFRAVLLDEKLDPALAAQILTLPSENEIAE 627
Cdd:pfam17432   1 DEDLAFLLAHDSDPFNRWEAGQTLALRLLLALVAALQAGEPLALDAAFIDAFRAVLADAALDPAFKAEALTLPSEAYLAE 80
                          90       100       110       120       130       140       150       160
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 1778700917 628 LFATIDPEAIAAVHEAIVRCLARELADEWLAVYHANKTDG-YRVEHAEIAKRALRNVCLGYLAFGEDVALADQLVnEQYR 706
Cdd:pfam17432  81 QMDVVDPDAIHAAREALRRALAEALRDELLALYQALAATGpYSPDAAAAGRRALRNLALSYLAAAGDPEAADLAA-AQFE 159
                         170       180       190       200       210       220       230       240
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 1778700917 707 QADNMTDALAALSAAVAAQLPCRDALLAAFDERWHQDGLVMDKWFVLQGGSPAADVLSKVRALLHHRSFSLSNPNRTRSL 786
Cdd:pfam17432 160 SADNMTDRLAALAALVNSDLPEREEALADFYQRWKDDPLVMDKWFALQATSPRPDTLERVKALMQHPAFDLKNPNRVRAL 239
                         250       260       270       280       290       300       310       320
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 1778700917 787 IGGFASGNPAAFHAADGSGYQFLAEILSDLNQRNPQIAARLIEPLIRLKRYDAGRQALMRKALEQLKGLENLSGDLYEKI 866
Cdd:pfam17432 240 IGAFAAANPVAFHAADGSGYRFLADQVLELDAINPQVAARLLTPLTRWRRYDPPRQALMRAALERIAATPGLSKDVFEIV 319

                  ....*
gi 1778700917 867 SKALD 871
Cdd:pfam17432 320 SKALA 324
 
Name Accession Description Interval E-value
pepN PRK14015
aminopeptidase N; Provisional
1-872 0e+00

aminopeptidase N; Provisional


Pssm-ID: 237585 [Multi-domain]  Cd Length: 875  Bit Score: 1706.10  E-value: 0e+00
                          10        20        30        40        50        60        70        80
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 1778700917   1 MTQQPQAKYRHDYRAPDYTTTDIDLDFSLDAETTRVTAVSKIKRQGAAG--APLVLDGEDLTLVSIQVDGQPWS--AYRQ 76
Cdd:PRK14015    2 RTQQPQAIYLKDYRPPDYLIDTVDLDFDLDPDKTRVTARLQVRRNPDAAhsAPLVLDGEDLELLSLALDGQPLApsAYEL 81
                          90       100       110       120       130       140       150       160
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 1778700917  77 QDNQLIIEELPAQFTLTIVNDIHPAKNTALEGLYLSGDALCTQCEAEGFHHITYYQDRPDVLARFTTRIVADKTRYPFLL 156
Cdd:PRK14015   82 DEEGLTIENLPDRFTLEIETEIDPEANTALEGLYRSGGMFCTQCEAEGFRRITYFLDRPDVLARYTVRIEADKAKYPVLL 161
                         170       180       190       200       210       220       230       240
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 1778700917 157 SNGNRIGQGELADGRHWVQWQDPFPKPCYLFALVAGDFDVLRDSFTTRSGRKVALELFVDRGNLDRADWAMTSLKNSMKW 236
Cdd:PRK14015  162 SNGNLVESGELPDGRHWATWEDPFPKPSYLFALVAGDLDVLEDTFTTRSGREVALEIYVEPGNLDKCDHAMDSLKKSMKW 241
                         250       260       270       280       290       300       310       320
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 1778700917 237 DETRFGLEYDLDIYMIVAVDFFNMGAMENKGLNIFNSKYVLAKAETATDKDYLNIEAVIGHEYFHNWTGNRVTCRDWFQL 316
Cdd:PRK14015  242 DEERFGLEYDLDIFMIVAVDDFNMGAMENKGLNIFNSKYVLADPETATDADYERIESVIAHEYFHNWTGNRVTCRDWFQL 321
                         330       340       350       360       370       380       390       400
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 1778700917 317 SLKEGLTVFRDQEFSSDLGSRSVNRIDNVRVMRGAQFAEDASPMAHAIRPDKVIEMNNFYTLTVYEKGSEVIRMMHTLLG 396
Cdd:PRK14015  322 SLKEGLTVFRDQEFSADLGSRAVKRIEDVRVLRAAQFAEDAGPMAHPVRPDSYIEINNFYTATVYEKGAEVIRMLHTLLG 401
                         410       420       430       440       450       460       470       480
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 1778700917 397 EENFQKGMQLYFERHDGSAATCDDFVQAMEDASNVDLSRFRRWYSQSGTPLLTVRDEYDAETQQYRLHVSQKTAPTADQP 476
Cdd:PRK14015  402 EEGFRKGMDLYFERHDGQAVTCEDFVAAMEDASGRDLSQFRRWYSQAGTPRVTVSDEYDAAAGTYTLTLSQSTPPTPGQP 481
                         490       500       510       520       530       540       550       560
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 1778700917 477 EKLPLHIPLDIELYDSEGNVIPLQKGGLPVNNVLNVTEAEQTFVFDGVAHKPVPSLLREFSAPVKLDYPYSDQQLTFLMQ 556
Cdd:PRK14015  482 EKQPLHIPVAIGLLDPDGKELPLQLEGEPVERVLELTEAEQTFTFENVAERPVPSLLRGFSAPVKLEYDYSDEDLLFLMA 561
                         570       580       590       600       610       620       630       640
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 1778700917 557 HARNEFARWDAAQSLLATYIKLNVARHqqKQPLSLPLHVADAFRAVLLDEKLDPALAAQILTLPSENEIAELFATIDPEA 636
Cdd:PRK14015  562 HDSDPFNRWEAGQRLATRLLLANVARH--GQPLSLDEALIDAFRAVLLDESLDPAFAAELLTLPSEAELAEQMEVIDPDA 639
                         650       660       670       680       690       700       710       720
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 1778700917 637 IAAVHEAIVRCLARELADEWLAVYHANKTDG-YRVEHAEIAKRALRNVCLGYLAFGEDvALADQLVNEQYRQADNMTDAL 715
Cdd:PRK14015  640 IHAAREALRRALATALKDELLALYEALQTDGpYSPDAEAAGRRALRNVCLSYLAAADD-EEAAELAEAQFDQADNMTDRL 718
                         730       740       750       760       770       780       790       800
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 1778700917 716 AALSAAVAAQLPCRDALLAAFDERWHQDGLVMDKWFVLQGGSPAADVLSKVRALLHHRSFSLSNPNRTRSLIGGFASGNP 795
Cdd:PRK14015  719 AALSALVNADLPERDEALADFYDRWKDDPLVMDKWFALQATSPAPDTLERVRALMQHPAFDLKNPNRVRSLIGAFAAANP 798
                         810       820       830       840       850       860       870
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*..
gi 1778700917 796 AAFHAADGSGYQFLAEILSDLNQRNPQIAARLIEPLIRLKRYDAGRQALMRKALEQLKGLENLSGDLYEKISKALDA 872
Cdd:PRK14015  799 AGFHAADGSGYRFLADQILALDKINPQVAARLATPLIRWRRYDPKRQALMRAALERIAALPNLSKDVREIVSKALAA 875
pepN_proteo TIGR02414
aminopeptidase N, Escherichia coli type; The M1 family of zinc metallopeptidases contains a ...
12-870 0e+00

aminopeptidase N, Escherichia coli type; The M1 family of zinc metallopeptidases contains a number of distinct, well-separated clades of proteins with aminopeptidase activity. Several are designated aminopeptidase N, EC 3.4.11.2, after the Escherichia coli enzyme, suggesting a similar activity profile (see SP|P04825 for a description of catalytic activity). This family consists of all aminopeptidases closely related to E. coli PepN and presumed to have similar (not identical) function. Nearly all are found in Proteobacteria, but members are found also in Cyanobacteria, plants, and apicomplexan parasites. This family differs greatly in sequence from the family of aminopeptidases typified by Streptomyces lividans PepN (TIGR02412), from the membrane bound aminopeptidase N family in animals, etc. [Protein fate, Degradation of proteins, peptides, and glycopeptides]


Pssm-ID: 274122 [Multi-domain]  Cd Length: 863  Bit Score: 1350.83  E-value: 0e+00
                          10        20        30        40        50        60        70        80
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 1778700917  12 DYRAPDYTTTDIDLDFSLDAETTRVTAVSKIKRQG-AAGAPLVLDGEDLTLVSIQVDGQPWSA--YRQQDNQLIIEELPA 88
Cdd:TIGR02414   1 DYKPPPFLIEKTHLDFDLHEEETVVRARLTVRRNPdGNGAPLVLDGEELKLLSIAIDGKPLAAgdYQLDDETLTIASVPE 80
                          90       100       110       120       130       140       150       160
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 1778700917  89 QFTLTIVNDIHPAKNTALEGLYLSGDALCTQCEAEGFHHITYYQDRPDVLARFTTRIVADKTRYPFLLSNGNRIGQGELA 168
Cdd:TIGR02414  81 SFTLEIETEIHPEENTSLEGLYKSGGNFCTQCEAEGFRRITYFPDRPDVMSRYTVTITADKKKYPVLLSNGNKIASGELP 160
                         170       180       190       200       210       220       230       240
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 1778700917 169 DGRHWVQWQDPFPKPCYLFALVAGDFDVLRDSFTTRSGRKVALELFVDRGNLDRADWAMTSLKNSMKWDETRFGLEYDLD 248
Cdd:TIGR02414 161 DGRHWAEWEDPFPKPSYLFALVAGDLDVLEDTFTTKSGREVALRVYVEEGNKDKCDHAMESLKKAMKWDEEVFGLEYDLD 240
                         250       260       270       280       290       300       310       320
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 1778700917 249 IYMIVAVDFFNMGAMENKGLNIFNSKYVLAKAETATDKDYLNIEAVIGHEYFHNWTGNRVTCRDWFQLSLKEGLTVFRDQ 328
Cdd:TIGR02414 241 IFMIVAVDDFNMGAMENKGLNIFNSKYVLADPETATDADYERIESVIAHEYFHNWTGNRVTCRDWFQLSLKEGLTVFRDQ 320
                         330       340       350       360       370       380       390       400
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 1778700917 329 EFSSDLGSRSVNRIDNVRVMRGAQFAEDASPMAHAIRPDKVIEMNNFYTLTVYEKGSEVIRMMHTLLGEENFQKGMQLYF 408
Cdd:TIGR02414 321 EFSADMTSRAVKRIEDVRLLRAHQFPEDAGPMAHPVRPESYVEINNFYTATVYEKGAEVIRMLHTLLGEEGFRKGMDLYF 400
                         410       420       430       440       450       460       470       480
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 1778700917 409 ERHDGSAATCDDFVQAMEDASNVDLSRFRRWYSQSGTPLLTVRDEYDAETQQYRLHVSQKTAPTADQPEKLPLHIPLDIE 488
Cdd:TIGR02414 401 SRHDGQAVTCEDFVAAMEDASGRDLNQFRRWYSQAGTPVLEVKENYDAAKKTYTLTVRQSTPPTPGQTEKKPLHIPIAVG 480
                         490       500       510       520       530       540       550       560
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 1778700917 489 LYDSEGNVIPLQ-KGGLPVNNVLNVTEAEQTFVFDGVAHKPVPSLLREFSAPVKLDYPYSDQQLTFLMQHARNEFARWDA 567
Cdd:TIGR02414 481 LLGPNGRKLMLSlDGERDTTRVLELTEAEQTFVFEGIAEKPVPSLLRGFSAPVNLEYPYSDEDLLLLLAHDSDPFNRWEA 560
                         570       580       590       600       610       620       630       640
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 1778700917 568 AQSLLATYIKLNVARHQQKQPLSLPLHVADAFRAVLLDEKLDPALAAQILTLPSENEIAELFATIDPEAIAAVHEAIVRC 647
Cdd:TIGR02414 561 GQRLARRVILANIARAQGGEELPVDPAFIDALGKLLNDPHLDAAFKALLLALPSEAYLAELMENIDPDALHAAREFLRAA 640
                         650       660       670       680       690       700       710       720
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 1778700917 648 LARELADEWLAVYHANKTDG-YRVEHAEIAKRALRNVCLGYLAFGEDvALADQLVNEQYRQADNMTDALAALSAAVAAQL 726
Cdd:TIGR02414 641 IARQLADDLLRLYDALQENGpYSVDPAAAGRRALRNACLSYLSAADD-AEIRNLALEQFKSADNMTDRLAALSALVHFES 719
                         730       740       750       760       770       780       790       800
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 1778700917 727 PCRDALLAAFDERWHQDGLVMDKWFVLQGGSPAADVLSKVRALLHHRSFSLSNPNRTRSLIGGFASGNPAAFHAADGSGY 806
Cdd:TIGR02414 720 DFRERALAAFYQKWKDDPLVMDKWFALQATSPRPDTLERVKALLQHPAFDLKNPNRVRALIGAFANNNLVRFHDISGSGY 799
                         810       820       830       840       850       860
                  ....*....|....*....|....*....|....*....|....*....|....*....|....
gi 1778700917 807 QFLAEILSDLNQRNPQIAARLIEPLIRLKRYDAGRQALMRKALEQLKGLENLSGDLYEKISKAL 870
Cdd:TIGR02414 800 RFLADQIIAIDRFNPQVAARLLEPLTRWRKLDPKRQELMKAALERIAAEENLSKDVREVVSKAL 863
M1_APN cd09600
Peptidase M1 family, including aminopeptidase N catalytic domain; This model represents the ...
12-441 0e+00

Peptidase M1 family, including aminopeptidase N catalytic domain; This model represents the catalytic domain of aminopeptidase N (APN; CD13; alanyl aminopeptidase; EC 3.4.11.2), a type II integral membrane protease belonging to the M1 gluzincin family. It includes bacterial-type alanyl aminopeptidases as well as PfA-M1 aminopeptidase (Plasmodium falciparum-type). APN preferentially cleaves neutral amino acids from the N-terminus of oligopeptides and, in higher eukaryotes, is present in a variety of human tissues and cell types (leukocyte, fibroblast, endothelial and epithelial cells). APN expression is dysregulated in inflammatory diseases such as chronic pain, rheumatoid arthritis, multiple sclerosis, systemic sclerosis, systemic lupus erythematosus, polymyositis/dermatomyosytis and pulmonary sarcoidosis, and is enhanced in tumor cells such as melanoma, renal, prostate, pancreas, colon, gastric and thyroid cancers. It is predominantly expressed on stem cells and on cells of the granulocytic and monocytic lineages at distinct stages of differentiation, thus considered a marker of differentiation. Thus, APN inhibition may lead to the development of anti-cancer and anti-inflammatory drugs. APNs are also present in many pathogenic bacteria and represent potential drug targets. Some APNs have been used commercially, such as one from Lactococcus lactis used in the food industry. APN also serves as a receptor for coronaviruses, although the virus receptor interaction site seems to be distinct from the enzymatic site and aminopeptidase activity is not necessary for viral infection. APNs have also been extensively studied as putative Cry toxin receptors. Cry1 proteins are pore-forming toxins that bind to the midgut epithelial cell membrane of susceptible insect larvae, causing extensive damage. Several different toxins, including Cry1Aa, Cry1Ab, Cry1Ac, Cry1Ba, Cry1Ca and Cry1Fa, have been shown to bind to APNs; however, a direct role of APN in cytotoxicity has been yet to be firmly established.


Pssm-ID: 341063 [Multi-domain]  Cd Length: 434  Bit Score: 868.76  E-value: 0e+00
                          10        20        30        40        50        60        70        80
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 1778700917  12 DYRAPDYTTTDIDLDFSLDAETTRVTAVSKIKRQGAA--GAPLVLDGEDLTLVSIQVDGQP--WSAYRQQDNQLIIEELP 87
Cdd:cd09600     1 DYKPPDFLIDHVDLDFDLDDDETIVTSRLRVRRNPDSgeGAPLVLDGEDLELLSVKIDGKPlsPSDYTLDEEGLTIKNVP 80
                          90       100       110       120       130       140       150       160
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 1778700917  88 AQFTLTIVNDIHPAKNTALEGLYLSGDALCTQCEAEGFHHITYYQDRPDVLARFTTRIVADKTRYPFLLSNGNRIGQGEL 167
Cdd:cd09600    81 DRFVLEIEVRINPAANTSLEGLYKSGGILCTQCEAEGFRRITYFPDRPDVMSKFTVTIEADKEKYPVLLSNGNLIEEGEL 160
                         170       180       190       200       210       220       230       240
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 1778700917 168 ADGRHWVQWQDPFPKPCYLFALVAGDFDVLRDSFTTRSGRKVALELFVDRGNLDRADWAMTSLKNSMKWDETRFGLEYDL 247
Cdd:cd09600   161 PNGRHFAVWEDPFPKPSYLFALVAGDLGSVEDTFTTKSGRKVKLRIYVEPGNEDKCHHAMESLKKAMKWDEERFGLEYDL 240
                         250       260       270       280       290       300       310       320
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 1778700917 248 DIYMIVAVDFFNMGAMENKGLNIFNSKYVLAKAETATDKDYLNIEAVIGHEYFHNWTGNRVTCRDWFQLSLKEGLTVFRD 327
Cdd:cd09600   241 DLFNIVAVDDFNMGAMENKGLNIFNSKYVLADPETATDADYERIESVIAHEYFHNWTGNRVTCRDWFQLSLKEGLTVFRD 320
                         330       340       350       360       370       380       390       400
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 1778700917 328 QEFSSDLGSRSVNRIDNVRVMRGAQFAEDASPMAHAIRPDKVIEMNNFYTLTVYEKGSEVIRMMHTLLGEENFQKGMQLY 407
Cdd:cd09600   321 QEFSADMNSRAVKRIEDVRRLRSAQFPEDAGPMAHPIRPDSYIEINNFYTVTVYEKGAEVIRMLHTLLGEEGFRKGMDLY 400
                         410       420       430
                  ....*....|....*....|....*....|....
gi 1778700917 408 FERHDGSAATCDDFVQAMEDASNVDLSRFRRWYS 441
Cdd:cd09600   401 FERHDGQAVTCEDFVAAMEDASGRDLSQFKRWYS 434
PepN COG0308
Aminopeptidase N, contains DUF3458 domain [Amino acid transport and metabolism];
10-649 0e+00

Aminopeptidase N, contains DUF3458 domain [Amino acid transport and metabolism];


Pssm-ID: 440077 [Multi-domain]  Cd Length: 609  Bit Score: 576.59  E-value: 0e+00
                          10        20        30        40        50        60        70        80
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 1778700917  10 RHDYRAPDYTTTDIDLDFSLDAETTRVTAVSKI--KRQGAAGAPLVLDGEDLTLVSIQVDGQPWsAYRQQDNQLII---E 84
Cdd:COG0308     7 LEAYRPPGYDVTHYDLDLDLDPATTRLSGTATItfTATEAPLDSLVLDLKGLEVTSVTVDGKPL-DFTRDGERLTItlpK 85
                          90       100       110       120       130       140       150       160
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 1778700917  85 ELPA--QFTLTIVNDIHPakNTALEGLYLSGDA------LCTQCEAEGFHhiTYY--QDRPDVLARFTTRIVADKtrYPF 154
Cdd:COG0308    86 PLAPgeTFTLEIEYSGKP--SNGGEGLYRSGDPpdgppyLYTQCEPEGAR--RWFpcFDHPDDKATFTLTVTVPA--GWV 159
                         170       180       190       200       210       220       230       240
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 1778700917 155 LLSNGNRIGQGELADGRHWVQWQDPFPKPCYLFALVAGDFDVLRDSFttRSGrkVALELFVDRGNLDRADWAMTSLKNSM 234
Cdd:COG0308   160 AVSNGNLVSETELGDGRTTWHWADTQPIPTYLFALAAGDYAVVEDTF--ASG--VPLRVYVRPGLADKAKEAFESTKRML 235
                         250       260       270       280       290       300       310       320
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 1778700917 235 KWDETRFGLEYDLDIYMIVAVDFFNMGAMENKGLNIFNSKYVLAkaETATDKDYLNIEAVIGHEYFHNWTGNRVTCRDWF 314
Cdd:COG0308   236 DFFEELFGVPYPFDKYDQVAVPDFNFGAMENQGLVTFGEKVLAD--ETATDADYERRESVIAHELAHQWFGNLVTCADWD 313
                         330       340       350       360       370       380       390       400
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 1778700917 315 QLSLKEGLTVFRDQEFSSDLGSRS-VNRIDnVRVMRGAQFAEDASPMAHAIRPDKVIEMNNFYTLTVYEKGSEVIRMMHT 393
Cdd:COG0308   314 DLWLNEGFATYMEQLFSEDLYGKDaADRIF-VGALRSYAFAEDAGPNAHPIRPDDYPEIENFFDGIVYEKGALVLHMLRT 392
                         410       420       430       440       450       460       470       480
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 1778700917 394 LLGEENFQKGMQLYFERHDGSAATCDDFVQAMEDASNVDLSR-FRRWYSQSGTPLLTVRDEYDAETqQYRLHVSQKtapt 472
Cdd:COG0308   393 LLGDEAFRAGLRLYFARHAGGNATTEDFLAALEEASGRDLSAfFDQWLYQAGLPTLEVEYEYDADG-KVTLTLRQT---- 467
                         490       500       510       520       530       540       550       560
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 1778700917 473 adQPEKLPLHIPLDIELYDsegnviplqkGGLPVNNVLnVTEAEQTFVfdgvaHKPVpsllrefsaPVKLDYPysDQQLT 552
Cdd:COG0308   468 --PPRPHPFHIPLEVGLLG----------GKLTARTVL-LDGEQTELV-----AKPD---------PVLLLRL--DDELA 518
                         570       580       590       600       610       620       630       640
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 1778700917 553 FLMQHARNEFARWDAAQSLlatyiklnvARHQQKQPLSLPLHVADAfravlldeklDPALAAQILTLPSENEIAELFATI 632
Cdd:COG0308   519 FLLAHDSDPFNRWEALQAL---------WRDGEADYLDALRALADT----------DPAVRAEALALLGSDQLALARAAL 579
                         650
                  ....*....|....*..
gi 1778700917 633 DPEAIAAVHEAIVRCLA 649
Cdd:COG0308   580 ALAAELALLRALDDLLA 596
DUF3458_C pfam17432
Domain of unknown function (DUF3458_C) ARM repeats; This presumed domain is functionally ...
548-871 8.43e-159

Domain of unknown function (DUF3458_C) ARM repeats; This presumed domain is functionally uncharacterized. This domain is found in bacteria, archaea and eukaryotes.


Pssm-ID: 465424 [Multi-domain]  Cd Length: 324  Bit Score: 466.61  E-value: 8.43e-159
                          10        20        30        40        50        60        70        80
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 1778700917 548 DQQLTFLMQHARNEFARWDAAQSLLATYIKLNVARHQQKQPLSLPLHVADAFRAVLLDEKLDPALAAQILTLPSENEIAE 627
Cdd:pfam17432   1 DEDLAFLLAHDSDPFNRWEAGQTLALRLLLALVAALQAGEPLALDAAFIDAFRAVLADAALDPAFKAEALTLPSEAYLAE 80
                          90       100       110       120       130       140       150       160
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 1778700917 628 LFATIDPEAIAAVHEAIVRCLARELADEWLAVYHANKTDG-YRVEHAEIAKRALRNVCLGYLAFGEDVALADQLVnEQYR 706
Cdd:pfam17432  81 QMDVVDPDAIHAAREALRRALAEALRDELLALYQALAATGpYSPDAAAAGRRALRNLALSYLAAAGDPEAADLAA-AQFE 159
                         170       180       190       200       210       220       230       240
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 1778700917 707 QADNMTDALAALSAAVAAQLPCRDALLAAFDERWHQDGLVMDKWFVLQGGSPAADVLSKVRALLHHRSFSLSNPNRTRSL 786
Cdd:pfam17432 160 SADNMTDRLAALAALVNSDLPEREEALADFYQRWKDDPLVMDKWFALQATSPRPDTLERVKALMQHPAFDLKNPNRVRAL 239
                         250       260       270       280       290       300       310       320
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 1778700917 787 IGGFASGNPAAFHAADGSGYQFLAEILSDLNQRNPQIAARLIEPLIRLKRYDAGRQALMRKALEQLKGLENLSGDLYEKI 866
Cdd:pfam17432 240 IGAFAAANPVAFHAADGSGYRFLADQVLELDAINPQVAARLLTPLTRWRRYDPPRQALMRAALERIAATPGLSKDVFEIV 319

                  ....*
gi 1778700917 867 SKALD 871
Cdd:pfam17432 320 SKALA 324
M1 cd09595
Peptidase M1 family includes the catalytic domains of aminopeptidase N and leukotriene A4 ...
21-427 9.41e-125

Peptidase M1 family includes the catalytic domains of aminopeptidase N and leukotriene A4 hydrolase; The model represents the catalytic domains of M1 peptidase family members including aminopeptidase N (APN) and leukotriene A4 hydrolase (LTA4H). All peptidases in this family bind a single catalytic zinc ion which is tetrahedrally co-ordinated by three amino acid ligands and a water molecule that forms the nucleophile upon activation during catalysis. APN preferentially cleaves neutral amino acids from the N-terminus of oligopeptides and is present in a variety of human tissues and cell types. APN expression is dysregulated in many inflammatory diseases and is enhanced in numerous tumor cells, making it a lead target in the development of anti-cancer and anti-inflammatory drugs. LTA4H is a bifunctional enzyme, possessing an aminopeptidase as well as an epoxide hydrolase activity. The two activities occupy different, but overlapping sites. The activity and physiological relevance of the aminopeptidase in LTA4H is as yet unknown, while the epoxide hydrolase converts leukotriene A4 (LTA4) into leukotriene B4 (LTB4), a potent chemotaxin that is fundamental to the inflammatory response of mammals.


Pssm-ID: 341058 [Multi-domain]  Cd Length: 413  Bit Score: 382.18  E-value: 9.41e-125
                          10        20        30        40        50        60        70        80
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 1778700917  21 TDIDLDFSLDAETTRVTAVSKIkRQGAAGAPLVLDGEDLTLVSIQVDGQP---WSAYRQQDNQLII---EELPAQFTLTI 94
Cdd:cd09595     3 YDLDLDVDFTTKTLNGTETLTV-DASQVGRELVLDLVGLTIHSVSVNGAAvdfGEREHYDGEKLTIpgpKPPGQTFTVRI 81
                          90       100       110       120       130       140       150       160
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 1778700917  95 VNDIHPAKNTAL----EGLYLSGDALCTQCEAEGFHHITYYQDRPDVLARFTTRIVADKtrYPFLLSNGNRIGQGELADG 170
Cdd:cd09595    82 SFEAKPSKNLLGwlweQTAGKEKPYLFTQFEATHARRIFPCIDHPAVKATFTVTITTPK--KDLLASNGALVGEETGANG 159
                         170       180       190       200       210       220       230       240
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 1778700917 171 RHWVQWQDPFPKPCYLFALVAGDFDVLRDSFTTRsgRKVALELFVDRGNLDRADWAMTSLKNSMKWDETRFGLEYDLDIY 250
Cdd:cd09595   160 RKTYRFEDTPPIPTYLVAVVVGDLEFKYVTVKSQ--PRVGLSVYSEPLQVDQAQYAFDATRAALAWFEDYFGGPYPLPKY 237
                         250       260       270       280       290       300       310       320
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 1778700917 251 MIVAVDFFNMGAMENKGLNIFNSKYVLAKAETATdkDYLNIEAVIGHEYFHNWTGNRVTCRDWFQLSLKEGLTVFRDQEF 330
Cdd:cd09595   238 DLLAVPDFNSGAMENPGLITFRTTYLLRSKVTDT--GARSIENVIAHELAHQWFGNLVTMRWWNDLWLNEGFAVYYENRI 315
                         330       340       350       360       370       380       390       400
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 1778700917 331 SSDLG---SRSVNRIDNVRVMRGAQFAEDASPMAHAIRPDkvIEMNNFYTLTVYEKGSEVIRMMHTLLGEENFQKGMQLY 407
Cdd:cd09595   316 MDATFgtsSRHLDQLSGSSDLNTEQLLEDSSPTSTPVRSP--ADPDVAYDGVTYAKGALVLRMLEELVGEEAFDKGVQAY 393
                         410       420
                  ....*....|....*....|
gi 1778700917 408 FERHDGSAATCDDFVQAMED 427
Cdd:cd09595   394 FNRHKFKNATTDDFIDALEE 413
Peptidase_M1 pfam01433
Peptidase family M1 domain; Members of this family are aminopeptidases. The members differ ...
225-439 1.11e-66

Peptidase family M1 domain; Members of this family are aminopeptidases. The members differ widely in specificity, hydrolysing acidic, basic or neutral N-terminal residues. This family includes leukotriene-A4 hydrolase, this enzyme also has an aminopeptidase activity.


Pssm-ID: 426262 [Multi-domain]  Cd Length: 219  Bit Score: 221.39  E-value: 1.11e-66
                          10        20        30        40        50        60        70        80
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 1778700917 225 WAMTSLKNSMKWDETRFGLEYDLDIYMIVAVDFFNMGAMENKGLNIFNSKYVLAKAETATDKDYLNIEAVIGHEYFHNWT 304
Cdd:pfam01433   1 YALEITVKLLEFYEDYFNIPYPLPKYDLVALPDFSAGAMENWGLITYRETLLLYDPGNSSTSDKQRVASVIAHELAHQWF 80
                          90       100       110       120       130       140       150       160
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 1778700917 305 GNRVTCRDWFQLSLKEGLTVFRDQEFSSDLGSRSVNRIDNVRVMRGAQFAEDASPMAHAI--RPDKVIEMNNFYTLTVYE 382
Cdd:pfam01433  81 GNLVTMKWWDDLWLNEGFATYMEYLGTDALFPEWNIWEQFLLDEVQNAMARDALDSSHPItqNVNDPSEIDDIFDAIPYE 160
                         170       180       190       200       210
                  ....*....|....*....|....*....|....*....|....*....|....*....
gi 1778700917 383 KGSEVIRMMHTLLGEENFQKGMQLYFERHDGSAATCDDFVQAMEDASN-VDLSRF-RRW 439
Cdd:pfam01433 161 KGASVLRMLETLLGEEVFQKGLRSYLKKFQYGNATTEDLWDALSEASGpLDVDSFmDTW 219
DUF3458 pfam11940
Domain of unknown function (DUF3458) Ig-like fold; This presumed domain is functionally ...
444-545 7.85e-51

Domain of unknown function (DUF3458) Ig-like fold; This presumed domain is functionally uncharacterized. This domain is found in bacteria, archaea and eukaryotes. The domain has an Ig-like fold. This domain is found associated with pfam01433.


Pssm-ID: 463405 [Multi-domain]  Cd Length: 95  Bit Score: 173.09  E-value: 7.85e-51
                          10        20        30        40        50        60        70        80
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 1778700917 444 GTPLLTVRDEYDAETQQYRLHVSQKTAPTADQPEKLPLHIPLDIELYDSEGNVIPLqkgglpvNNVLNVTEAEQTFVFDG 523
Cdd:pfam11940   1 GTPRVTVSDSYDAAAGTYTLTLSQTTPPTPGQPEKQPLHIPIRIALLDPNGQELAL-------ERVLELTEAEQTFTFEG 73
                          90       100
                  ....*....|....*....|..
gi 1778700917 524 VAHKPVPSLLREFSAPVKLDYP 545
Cdd:pfam11940  74 VAEKPVPSLLRGFSAPVKLEYD 95
M1_APN_like cd09603
Peptidase M1 family similar to aminopeptidase N catalytic domain; This family contains mostly ...
18-440 2.89e-49

Peptidase M1 family similar to aminopeptidase N catalytic domain; This family contains mostly bacterial and some archaeal M1 peptidases with smilarity to the catalytic domain of aminopeptidase N (APN; CD13; alanyl aminopeptidase; EC 3.4.11.2), a type II integral membrane protease belonging to the M1 gluzincin family. APN preferentially cleaves neutral amino acids from the N-terminus of oligopeptides and, in higher eukaryotes, is present in a variety of human tissues and cell types (leukocyte, fibroblast, endothelial and epithelial cells). APN expression is dysregulated in inflammatory diseases such as chronic pain, rheumatoid arthritis, multiple sclerosis, systemic sclerosis, systemic lupus erythematosus, polymyositis/dermatomyosytis and pulmonary sarcoidosis, and is enhanced in tumor cells such as melanoma, renal, prostate, pancreas, colon, gastric and thyroid cancers. It is predominantly expressed on stem cells and on cells of the granulocytic and monocytic lineages at distinct stages of differentiation, thus considered a marker of differentiation. Thus, APN inhibition may lead to the development of anti-cancer and anti-inflammatory drugs. APNs are also present in many pathogenic bacteria and represent potential drug targets. Some APNs have been used commercially, such as one from Lactococcus lactis used in the food industry. APN also serves as a receptor for coronaviruses, although the virus receptor interaction site seems to be distinct from the enzymatic site and aminopeptidase activity is not necessary for viral infection. APNs have also been extensively studied as putative Cry toxin receptors. Cry1 proteins are pore-forming toxins that bind to the midgut epithelial cell membrane of susceptible insect larvae, causing extensive damage. Several different toxins, including Cry1Aa, Cry1Ab, Cry1Ac, Cry1Ba, Cry1Ca and Cry1Fa, have been shown to bind to APNs; however, a direct role of APN in cytotoxicity has been yet to be firmly established.


Pssm-ID: 341066 [Multi-domain]  Cd Length: 410  Bit Score: 179.70  E-value: 2.89e-49
                          10        20        30        40        50        60        70        80
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 1778700917  18 YTTTDIDLDFSLDAETTRVTAVSKIK---RQGAAGapLVLDGEDLTLVSIQVDGQPWSAYRQQDNQLII---EELPA--Q 89
Cdd:cd09603     1 YDVLHYDLDLDYDPATKSLSGTATITfraTQDLDS--LQLDLVGLTVSSVTVDGVPAAFFTHDGDKLVItlpRPLAAgeT 78
                          90       100       110       120       130       140       150       160
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 1778700917  90 FTLTIVNDIHPAKNT----ALEGLYLSGDALCTQCEAEGFHHI--TYyqDRPDVLARFTTRIVADKTRYPflLSNGNRIG 163
Cdd:cd09603    79 FTVTVRYSGKPRPAGyppgDGGGWEEGDDGVWTAGQPEGASTWfpCN--DHPDDKATYDITVTVPAGLTV--VSNGRLVS 154
                         170       180       190       200       210       220       230       240
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 1778700917 164 QGELADGRHWVQWQDPFPKPCYLFALVAGDFDVlrdsFTTRSGRKVALELFVDRGNLDRADWAMTSLKNSMKWDETRFGl 243
Cdd:cd09603   155 TTTNGGGTTTWHWKMDYPIATYLVTLAVGRYAV----VEDGSGGGIPLRYYVPPGDAAKAKASFARTPEMLDFFEELFG- 229
                         250       260       270       280       290       300       310       320
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 1778700917 244 EYDLDIYMIVAVDFFNmGAMENKGLNIFNSKYVlakaetatdKDYLNIEAVIGHEYFHNWTGNRVTCRDWFQLSLKEGLT 323
Cdd:cd09603   230 PYPFEKYGQVVVPDLG-GGMEHQTATTYGNNFL---------NGDRGSERLIAHELAHQWFGDSVTCADWADIWLNEGFA 299
                         330       340       350       360       370       380       390       400
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 1778700917 324 VFRDQEFSSDLGSRsvnridnvRVMRGAQFAEDASPMAHAIRPDKVIEMNNFYTLTVYEKGSEVIRMMHTLLGEENFQKG 403
Cdd:cd09603   300 TYAEWLWSEHKGGA--------DAYRAYLAGQRQDYLNADPGPGRPPDPDDLFDRDVYQKGALVLHMLRNLLGDEAFFAA 371
                         410       420       430
                  ....*....|....*....|....*....|....*...
gi 1778700917 404 MQLYFERHDGSAATCDDFVQAMEDASNVDLSR-FRRWY 440
Cdd:cd09603   372 LRAYLARYAHGNVTTEDFIAAAEEVSGRDLTWfFDQWL 409
M1_APN cd09602
Peptidase M1 family including aminopeptidase N catalytic domain; This model represents the ...
13-439 1.07e-47

Peptidase M1 family including aminopeptidase N catalytic domain; This model represents the catalytic domain of bacterial and eukaryotic aminopeptidase N (APN; CD13; alanyl aminopeptidase; EC 3.4.11.2), a type II integral membrane protease belonging to the M1 gluzincin family. APN preferentially cleaves neutral amino acids from the N-terminus of oligopeptides and, in higher eukaryotes, is present in a variety of human tissues and cell types (leukocyte, fibroblast, endothelial and epithelial cells). APN expression is dysregulated in inflammatory diseases such as chronic pain, rheumatoid arthritis, multiple sclerosis, systemic sclerosis, systemic lupus erythematosus, polymyositis/dermatomyosytis and pulmonary sarcoidosis, and is enhanced in tumor cells such as melanoma, renal, prostate, pancreas, colon, gastric and thyroid cancers. It is predominantly expressed on stem cells and on cells of the granulocytic and monocytic lineages at distinct stages of differentiation, thus considered a marker of differentiation. Thus, APN inhibition may lead to the development of anti-cancer and anti-inflammatory drugs. APNs are also present in many pathogenic bacteria and represent potential drug targets. Some APNs have been used commercially, such as one from Lactococcus lactis used in the food industry. APN also serves as a receptor for coronaviruses, although the virus receptor interaction site seems to be distinct from the enzymatic site and aminopeptidase activity is not necessary for viral infection. APNs have also been extensively studied as putative Cry toxin receptors. Cry1 proteins are pore-forming toxins that bind to the midgut epithelial cell membrane of susceptible insect larvae, causing extensive damage. Several different toxins, including Cry1Aa, Cry1Ab, Cry1Ac, Cry1Ba, Cry1Ca and Cry1Fa, have been shown to bind to APNs; however, a direct role of APN in cytotoxicity has been yet to be firmly established.


Pssm-ID: 341065 [Multi-domain]  Cd Length: 440  Bit Score: 176.17  E-value: 1.07e-47
                          10        20        30        40        50        60        70        80
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 1778700917  13 YRAPDYTTTDIDLDFSLDAETTRVTAVSKIK-RQGAAGAPLVLDGEDLTLVSIQVDGQPWSAYRQQDNQLIIEELPAQFT 91
Cdd:cd09602     8 QRAALISVVSYDLDLDLTEGAETFRGTVTIRfTLREPGASLFLDFRGGEVKSVTLNGRPLDPSAFDGERITLPGLLKAGE 87
                          90       100       110       120       130       140       150       160
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 1778700917  92 LTIVNDIHPAKNTALEGLYLSGDA------LCTQCEAEGFHHITYYQDRPDVLARFTTRIVADK--TrypfLLSNGNRIG 163
Cdd:cd09602    88 NTVVVEFTAPYSSDGEGLHRFVDPadgetyLYTLFEPDDARRVFPCFDQPDLKATFTLTVTAPAdwT----VISNGPETS 163
                         170       180       190       200       210       220       230       240
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 1778700917 164 QGELADGRHWVqwqdpFPK----PCYLFALVAGDFDVLRDSfttrsGRKVALELFVDRG----NLDRADW-AMTslKNSM 234
Cdd:cd09602   164 TEEAGGRKRWR-----FAEtpplSTYLFAFVAGPYHRVEDE-----HDGIPLGLYCRESlaeyERDADEIfEVT--KQGL 231
                         250       260       270       280       290       300       310       320
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 1778700917 235 KWDETRFGLEYDLDIYMIVAVDFFNMGAMENKGLNIFNSKYVLAkaETATDKDYLNIEAVIGHEYFHNWTGNRVTCRDWF 314
Cdd:cd09602   232 DFYEDYFGIPYPFGKYDQVFVPEFNFGAMENPGAVTFRESYLFR--EEPTRAQRLRRANTILHEMAHMWFGDLVTMKWWD 309
                         330       340       350       360       370       380       390       400
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 1778700917 315 QLSLKEgltVFRDqeFSSDLGSRSVNRIDNVRV-----MRGAQFAEDASPMAHAIRPDkvIE-----MNNFYTLTvYEKG 384
Cdd:cd09602   310 DLWLNE---SFAD--FMAAKALAEATPFTDAWLtfllrRKPWAYRADQLPTTHPIAQD--VPdleaaGSNFDGIT-YAKG 381
                         410       420       430       440       450
                  ....*....|....*....|....*....|....*....|....*....|....*.
gi 1778700917 385 SEVIRMMHTLLGEENFQKGMQLYFERHDGSAATCDDFVQAMEDASNVDLSRF-RRW 439
Cdd:cd09602   382 ASVLKQLVALVGEEAFRAGLREYFKKHAYGNATLDDLIAALDEASGRDLSAWaDAW 437
M1_APN-Q_like cd09601
Peptidase M1 aminopeptidase N catalytic domain family which includes aminopeptidase N (APN), ...
52-434 1.16e-45

Peptidase M1 aminopeptidase N catalytic domain family which includes aminopeptidase N (APN), aminopeptidase Q (APQ), tricorn interacting factor F3, and endoplasmic reticulum aminopeptidase 1 (ERAP1); This M1 peptidase family includes eukaryotic and bacterial members: the catalytic domains of aminopeptidase N (APN), aminopeptidase Q (APQ, laeverin), endoplasmic reticulum aminopeptidase 1 (ERAP1) as well as tricorn interacting factor F3. Aminopeptidase N (APN; CD13; alanyl aminopeptidase; EC 3.4.11.2), a type II integral membrane protease, preferentially cleaves neutral amino acids from the N-terminus of oligopeptides and is present in a variety of human tissues and cell types (leukocyte, fibroblast, endothelial and epithelial cells). APN expression is dysregulated in inflammatory diseases such as chronic pain, rheumatoid arthritis, multiple sclerosis, systemic sclerosis, systemic lupus erythematosus, polymyositis/dermatomyosytis and pulmonary sarcoidosis, and is enhanced in tumor cells such as melanoma, renal, prostate, pancreas, colon, gastric and thyroid cancers. It is considered a marker of differentiation since it is predominantly expressed on stem cells and on cells of the granulocytic and monocytic lineages at distinct stages of differentiation. Thus, APN inhibition may lead to the development of anti-cancer and anti-inflammatory drugs. ERAP1, also known as endoplasmic reticulum aminopeptidase associated with antigen processing (ERAAP), adipocyte derived leucine aminopeptidase (A-LAP), or aminopeptidase regulating tumor necrosis factor receptor I (THFRI) shedding (ARTS-1), associates with the closely related ER aminopeptidase ERAP2, for the final trimming of peptides within the ER for presentation by MHC class I molecules. ERAP1 is associated with ankylosing spondylitis (AS), an inflammatory arthritis that predominantly affects the spine. ERAP1 also aids in the shedding of membrane-bound cytokine receptors. The tricorn interacting factor F3, together with factors F1 and F2, degrades the tricorn protease products, producing free amino acids, thus completing the proteasomal degradation pathway. F3 is homologous to F2, but not F1, and shows a strong preference for glutamate in the P1' position. APQ, also known as laeverin, is specifically expressed in human embryo-derived extravillous trophoblasts (EVTs) that invade the uterus during early placentation. It cleaves the N-terminal amino acid of various peptides such as angiotensin III, endokinin C, and kisspeptin-10, all expressed in the placenta in large quantities. APN is a receptor for coronaviruses, although the virus receptor interaction site seems to be distinct from the enzymatic site and aminopeptidase activity is not necessary for viral infection. APNs are also putative Cry toxin receptors. Cry1 proteins are pore-forming toxins that bind to the midgut epithelial cell membrane of susceptible insect larvae, causing extensive damage. Several different toxins, including Cry1Aa, Cry1Ab, Cry1Ac, Cry1Ba, Cry1Ca and Cry1Fa, have been shown to bind to APNs; however, a direct role of APN in cytotoxicity has been yet to be firmly established.


Pssm-ID: 341064 [Multi-domain]  Cd Length: 442  Bit Score: 170.07  E-value: 1.16e-45
                          10        20        30        40        50        60        70        80
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 1778700917  52 LVLDGEDLTLVSIQVDGQPWSAYRQQDNQLII---EELPA--QFTLTI-----VNDIhpakntaLEGLYLS--GDA---- 115
Cdd:cd09601    40 LTITSASLTLKGGSGIIEVTVVTDEETEFLTItldETLPPgeNYTLSIeftgkLNDD-------LRGFYRSsyTDEdget 112
                          90       100       110       120       130       140       150       160
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 1778700917 116 ---LCTQCEAEG-------FhhityyqDRPDVLARFTTRIVADKTRYPflLSNGNRIGQGELADGRHWVQwqdpF---PK 182
Cdd:cd09601   113 rylAATQFEPTDarrafpcF-------DEPAFKATFDITITHPKGYTA--LSNMPPVESTELEDGWKTTT----FettPP 179
                         170       180       190       200       210       220       230       240
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 1778700917 183 -PCYLFALVAGDFDVLrdsfTTRSGRKVALELFVDRGNLDRADWAMTSLKNSMKWDETRFGLEYDL---DIymiVAVDFF 258
Cdd:cd09601   180 mSTYLVAFVVGDFEYI----ESTTKSGVPVRVYARPGKIEQGDFALEVAPKILDFYEDYFGIPYPLpklDL---VAIPDF 252
                         250       260       270       280       290       300       310       320
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 1778700917 259 NMGAMENKGLNIFNSKYVLAKAETATDKDYLNIEAVIGHEYFHNWTGNRVTCRDWFQLSLKEGltvfrdqeFSSDLGSRS 338
Cdd:cd09601   253 AAGAMENWGLITYRETALLYDPKTSSASDKQRVAEVIAHELAHQWFGNLVTMKWWDDLWLNEG--------FATYMEYLA 324
                         330       340       350       360       370       380       390       400
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 1778700917 339 VNRID---------NVRVMRGAqFAEDASPMAHAIRPD--KVIEMNNFYTLTVYEKGSEVIRMMHTLLGEENFQKGMQLY 407
Cdd:cd09601   325 VDKLFpewnmwdqfVVDELQSA-LELDSLASSHPIEVPveSPSEISEIFDAISYSKGASVLRMLENFLGEEVFRKGLRKY 403
                         410       420
                  ....*....|....*....|....*..
gi 1778700917 408 FERHDGSAATCDDFVQAMEDASNVDLS 434
Cdd:cd09601   404 LKKHAYGNATTDDLWEALQEASGESKP 430
leuko_A4_hydro TIGR02411
leukotriene A-4 hydrolase/aminopeptidase; Members of this family represent a distinctive ...
17-446 1.57e-20

leukotriene A-4 hydrolase/aminopeptidase; Members of this family represent a distinctive subset within the zinc metallopeptidase family M1 (pfam01433). The majority of the members of pfam01433 are aminopeptidases, but the sequences in this family for which the function is known are leukotriene A-4 hydrolase. A dual epoxide hydrolase and aminopeptidase activity at the same active site is indicated. The physiological substrate for aminopeptidase activity is not known.


Pssm-ID: 274120 [Multi-domain]  Cd Length: 602  Bit Score: 96.77  E-value: 1.57e-20
                          10        20        30        40        50        60        70        80
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 1778700917  17 DYTTTDIDLDFSLDAETTRV--TAVSKIKRQGAAGAPLVLDGEDLTLVSIQVDGQPwSAYRQQDNQLIIEElpaqfTLTI 94
Cdd:TIGR02411  10 DFRTSHTDLNLSVDFTKRKLsgSVTFTLKSLTDNLNKLVLDTSYLDIQKVTINGLP-ADFAIGERKEPLGS-----PLTI 83
                          90       100       110       120       130       140       150       160
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 1778700917  95 VNDIHPAKN---------------TALEGL----YLSGDA--LCTQCEAEGFHHITYYQDRPDVLARFTTRIvadKTRYP 153
Cdd:TIGR02411  84 SLPIATSKNdefvlnisfsttpkcTALQWLnpeqTSGKKHpyLFSQCQAIHARSLFPCQDTPSVKSTYTAEV---ESPLP 160
                         170       180       190       200       210       220       230       240
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 1778700917 154 FLLSnGNRIGQGELADGRHwvQWQDPFPKPCYLFALVAGDFDvlRDSFTTRSgrkvalELFVDRGNLDRADWAMTSLKNS 233
Cdd:TIGR02411 161 VLMS-GIRDGETSNDPGKY--LFKQKVPIPAYLIAIASGDLA--SAPIGPRS------TVYSEPEQLEKCQYEFENDTEK 229
                         250       260       270       280       290       300       310       320
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 1778700917 234 MKWDETRFGLEYDLDIY-MIVAVDFFNMGAMENKGLNiFNSKYVLAKaetatDKDYLNieaVIGHEYFHNWTGNRVTCRD 312
Cdd:TIGR02411 230 FIKTAEDLIFPYEWGQYdLLVLPPSFPYGGMENPNLT-FATPTLIAG-----DRSNVD---VIAHELAHSWSGNLVTNCS 300
                         330       340       350       360       370       380       390       400
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 1778700917 313 WFQLSLKEGLTVF------------RDQEFSSDLGSRSVNriDNVRVMrgaqfaEDASPMAHAIRPDKVIEMNNFYTLTV 380
Cdd:TIGR02411 301 WEHFWLNEGWTVYlerriigrlygeKTRHFSALIGWGDLQ--ESVKTL------GETPEFTKLVVDLKDNDPDDAFSSVP 372
                         410       420       430       440       450       460       470
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....
gi 1778700917 381 YEKGSEVIRMMHTLLG-EENFQKGMQLYFERHDGSAATCDDFVQAMED-------ASNVDLSRFRRWYSQSGTP 446
Cdd:TIGR02411 373 YEKGFNFLFYLEQLLGgPAEFDPFLRHYFKKFAYKSLDTYQFKDALYEyfkdkkkVDKLDAVDWETWLYSPGMP 446
Peptidase_M1_N pfam17900
Peptidase M1 N-terminal domain; This domain is found at the N-terminus of aminopeptidases from ...
24-186 8.05e-18

Peptidase M1 N-terminal domain; This domain is found at the N-terminus of aminopeptidases from the M1 family.


Pssm-ID: 465557 [Multi-domain]  Cd Length: 186  Bit Score: 82.39  E-value: 8.05e-18
                          10        20        30        40        50        60        70        80
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 1778700917  24 DLDFSLDAETTRVTAVSKIKRQGAAGA-PLVLDGEDLTLVSIQVDGQPWSAYR-------QQDNQLIIEELPA------Q 89
Cdd:pfam17900   6 DLDLKIDLKNFTFSGSVTITLQLNNATnVIVLHASDLTIRSISLSDEVTSDGVpadftedQKDGEKLTIVLPEtlnqtgP 85
                          90       100       110       120       130       140       150       160
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 1778700917  90 FTLTI--VNDIhpakNTALEGLYLS--------GDALCTQCEAEGFHHITYYQDRPDVLARFTTRIVADKTRypFLLSNG 159
Cdd:pfam17900  86 YTLEIeySGEL----NDSMTGFYRStytdngekKVLVTTQFEPTDARSAFPCFDEPSVKATFTISIIHPKDY--TALSNM 159
                         170       180
                  ....*....|....*....|....*..
gi 1778700917 160 NRIGQGELADGRHWVQWQDPFPKPCYL 186
Cdd:pfam17900 160 PVIASEPLENGWVITTFEQTPKMSTYL 186
M1_APN_like cd09604
Peptidase M1 family similar to aminopeptidase N catalytic domain; This family contains ...
187-440 2.61e-16

Peptidase M1 family similar to aminopeptidase N catalytic domain; This family contains bacterial M1 peptidases with smilarity to the catalytic domain of aminopeptidase N (APN; CD13; alanyl aminopeptidase; EC 3.4.11.2), a type II integral membrane protease belonging to the M1 gluzincin family. APN preferentially cleaves neutral amino acids from the N-terminus of oligopeptides and, in higher eukaryotes, is present in a variety of human tissues and cell types (leukocyte, fibroblast, endothelial and epithelial cells). APN expression is dysregulated in inflammatory diseases such as chronic pain, rheumatoid arthritis, multiple sclerosis, systemic sclerosis, systemic lupus erythematosus, polymyositis/dermatomyosytis and pulmonary sarcoidosis, and is enhanced in tumor cells such as melanoma, renal, prostate, pancreas, colon, gastric and thyroid cancers. It is predominantly expressed on stem cells and on cells of the granulocytic and monocytic lineages at distinct stages of differentiation, thus considered a marker of differentiation. Thus, APN inhibition may lead to the development of anti-cancer and anti-inflammatory drugs. APNs are also present in many pathogenic bacteria and represent potential drug targets. Some APNs have been used commercially, such as one from Lactococcus lactis used in the food industry. APN also serves as a receptor for coronaviruses, although the virus receptor interaction site seems to be distinct from the enzymatic site and aminopeptidase activity is not necessary for viral infection. APNs have also been extensively studied as putative Cry toxin receptors. Cry1 proteins are pore-forming toxins that bind to the midgut epithelial cell membrane of susceptible insect larvae, causing extensive damage. Several different toxins, including Cry1Aa, Cry1Ab, Cry1Ac, Cry1Ba, Cry1Ca and Cry1Fa, have been shown to bind to APNs; however, a direct role of APN in cytotoxicity has been yet to be firmly established.


Pssm-ID: 341067 [Multi-domain]  Cd Length: 440  Bit Score: 82.32  E-value: 2.61e-16
                          10        20        30        40        50        60        70        80
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 1778700917 187 FALVAGDfdvlrdSFTTRSGRK--VALELFVDRGNLDRADWAMTSLKNSMKWDETRFGlEYDLDIYMIVAVDFFNmGAME 264
Cdd:cd09604   204 FAWAASP------DFVVDAATVdgVTVNVYYLPENAEAAERALEYAKDALEFFSEKFG-PYPYPELDVVQGPFGG-GGME 275
                          90       100       110       120       130       140       150       160
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 1778700917 265 NKGLnIFNSKYVlakaetatDKDYLNIEAVIGHEYFHNW----TGNrvtcrD-----WfqlsLKEGLTvfrdqEFSSDLG 335
Cdd:cd09604   276 YPGL-VFIGSRL--------YDPKRSLEGVVVHEIAHQWfygiVGN-----DerrepW----LDEGLA-----TYAESLY 332
                         170       180       190       200       210       220       230       240
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 1778700917 336 SRSVNRIDNvrvmrGAQFAEDASPMAHAIRPDKVIEM-------NNFYTLTVYEKGSEVIRMMHTLLGEENFQKGMQLYF 408
Cdd:cd09604   333 LEEKYGKEA-----ADELLGRRYYRAYARGPGGPINLpldtfpdGSYYSNAVYSKGALFLEELREELGDEAFDKALREYY 407
                         250       260       270
                  ....*....|....*....|....*....|...
gi 1778700917 409 ERHDGSAATCDDFVQAMEDASNVDLSRF-RRWY 440
Cdd:cd09604   408 RRYKFKHPTPEDFFRTAEEVSGKDLDWFfRGWL 440
M1_LTA4H cd09599
Peptidase M1 family including Leukotriene A4 hydrolase catalytic domain; This model represents ...
17-427 5.72e-16

Peptidase M1 family including Leukotriene A4 hydrolase catalytic domain; This model represents the N-terminal catalytic domain of leukotriene A4 hydrolase (LTA4H; E.C. 3.3.2.6) and the close homolog cold-active aminopeptidase (Colwellia psychrerythraea-type peptidase; ColAP), both members of the aminopeptidase M1 family. LTA4H is a bifunctional enzyme, possessing an aminopeptidase as well as an epoxide hydrolase activity. The two activities occupy different, but overlapping sites. The activity and physiological relevance of the aminopeptidase is poorly understood while the epoxide hydrolase converts leukotriene A4 (LTA4) into leukotriene B4 (LTB4), a potent chemotaxin that is fundamental to the inflammatory response of mammals. It accepts a variety of substrates, including some opioid, di- and tripeptides, as well as chromogenic aminoacyl-p-nitroanilide derivatives. The aminopeptidase activity of LTA4H is possibly involved in the processing of peptides related to inflammation and host defense. Kinetic analysis shows that LTA4H hydrolyzes arginyl tripeptides with high efficiency and specificity, indicating its function as an arginyl aminopeptidase. Thermodynamic characterization using different biophysical methods shows that structurally distinct inhibitors of the LTA4H occupy different regions of the binding site; while some (RB202, ARM1 and SC57461A) bind to the hydrophobic hydrolase side, both bestatin and captopril are located at the hydrophilic peptidase side. LTB4H overexpression is associated with different pathological conditions and diseases such as cystic fibrosis, coronary heart disease, sepsis, shock, connective tissue disease, and chronic obstructive pulmonary disease. It is also overexpressed in certain human cancers, and has been identified as a functionally important target for mediating anticancer properties of resveratrol, a well-known red wine polyphenolic compound with cancer chemopreventive activity.


Pssm-ID: 341062 [Multi-domain]  Cd Length: 442  Bit Score: 81.35  E-value: 5.72e-16
                          10        20        30        40        50        60        70        80
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 1778700917  17 DYTTTDIDLDFSLDAETTRV--TAVSKIKRQGAAGAPLVLDGEDLTLVSIQVDGqpwsayrqqdnqliieELPAQFTLti 94
Cdd:cd09599    10 EVRTTHLDLDLTVDFDKKTIsgSATLTLEVLQDGADELVLDTRDLDISSVTVNG----------------GKELKFEL-- 71
                          90       100       110       120       130       140       150       160
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 1778700917  95 vNDIHPAKNTALE----GLYLSGD---------------ALC----------------TQCEAegfhhItyY-------Q 132
Cdd:cd09599    72 -GPRDPVLGSALTitlpSPLAKGDtfkvkieysttpqatALQwltpeqtagkkhpylfTQCQA-----I--HarslfpcQ 143
                         170       180       190       200       210       220       230       240
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 1778700917 133 DRPDVLARFTTRIVADKtRYPFLLSnGNRIGQGELADGR--HWVQwqdPFPKPCYLFALVAGDFdVLRDsFTTRSGrkva 210
Cdd:cd09599   144 DTPSVKSTYSATVTVPK-GLTALMS-ALRTGEKEEAGTGtyTFEQ---PVPIPSYLIAIAVGDL-ESRE-IGPRSG---- 212
                         250       260       270       280       290       300       310       320
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 1778700917 211 leLFVDRGNLDRADWAMTSLKNSMKWDETRFGlEYDLDIY-MIVAVDFFNMGAMENKGLnIFNSKYVLAKAETATDkdyl 289
Cdd:cd09599   213 --VWAEPSVVDAAAEEFADTEKFLKAAEKLYG-PYVWGRYdLLVLPPSFPYGGMENPCL-TFATPTLIAGDRSLVD---- 284
                         330       340       350       360       370       380       390       400
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 1778700917 290 nieaVIGHEYFHNWTGNRVTCRDWFQLSLKEGLTVF--RdqefssdlgsrsvnRIdnVRVMRGAQFAE-----DASPMAH 362
Cdd:cd09599   285 ----VIAHEIAHSWSGNLVTNANWEHFWLNEGFTVYleR--------------RI--LERLYGEEYRQfeailGWKDLQE 344
                         410       420       430       440       450       460       470       480
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 1778700917 363 AIrpdKVIEMNNFYTLTV----------------YEKGSEVIRMMHTLLGEENFQKGMQLYFERHDGSAATCDDFVQAME 426
Cdd:cd09599   345 SI---KEFGEDPPYTLLVpdlkgvdpddafssvpYEKGFQFLYYLEQLGGREVFDPFLRAYFKKFAFQSIDTEDFKDFLL 421

                  .
gi 1778700917 427 D 427
Cdd:cd09599   422 E 422
 
Blast search parameters
Data Source: Precalculated data, version = cdd.v.3.21
Preset Options:Database: CDSEARCH/cdd   Low complexity filter: no  Composition Based Adjustment: yes   E-value threshold: 0.01

References:

  • Wang J et al. (2023), "The conserved domain database in 2023", Nucleic Acids Res.51(D)384-8.
  • Lu S et al. (2020), "The conserved domain database in 2020", Nucleic Acids Res.48(D)265-8.
  • Marchler-Bauer A et al. (2017), "CDD/SPARCLE: functional classification of proteins via subfamily domain architectures.", Nucleic Acids Res.45(D)200-3.
Help | Disclaimer | Write to the Help Desk
NCBI | NLM | NIH